<DOC>
	<DOC>NCT00401635</DOC>
	<brief_summary>The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.</brief_summary>
	<brief_title>END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin</brief_title>
	<detailed_description>Treatment is planned with carboplatin AUC 5 given IV on day 1 and liposomal doxorubicin 40 mg/m2 given IV on day 1, with treatment repeated every 28 days. Delays in treatment administration and dose reductions have been planned according to toxicity.</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Cytologic / histologic diagnosis of endometrial carcinoma Indication for chemotherapy Age 75 years or less Life expectancy of at least 3 months Measurable disease &gt; 1 cm Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or insitu carcinoma of the uterine cervix, provided they are being adequately treated) Performance status (ECOG) &gt; 2 Previous chemotherapy treatment Heart disease (heart failure, myocardial heart attack within 6 months prior to randomization, atrioventricular block of any degree, serious arrhythmia) Leukocytes &lt; 4000/mm3, platelets &lt; 100000/mm3 Impaired renal function (creatinine &gt; o = 1.25 times the upper normal limit) or liver function (SGOT or SGPT &gt; o = 1.25 times the upper normal limit) Present or suspected hemorrhagic syndromes Uncooperative and/or unreliable patients Patient's inability to access the center Refusal of informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>advanced</keyword>
	<keyword>recurrent</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>first-line</keyword>
</DOC>